Amarin (AMRN) P/E (2010 - 2026)
Amarin (AMRN) P/E from Sep 30, 2010 to Jul 20, 2026. The TTM Amarin (AMRN) P/E is -8.43. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Amarin (AMRN)
| Year | P/E | Change |
|---|---|---|
| 2026 | -8.43 | +12.98% |
| 2025 | -7.47 | +207.48% |
| 2024 | -2.43 | -64.12% |
| 2023 | -6.77 | +29.31% |
| 2022 | -5.23 | -103.02% |
| 2021 | 173.20 | -278.02% |
| 2020 | -97.29 | -68.49% |
| 2019 | -308.76 | +767.17% |
| 2018 | -35.61 | +139.33% |
| 2017 | -14.88 | +269.41% |
| 2016 | -4.03 | +170.41% |
| 2015 | -1.49 | -1.65% |
| 2014 | -1.51 | +61.24% |
| 2013 | -0.94 | -70.80% |
| 2012 | -3.22 | -33.71% |
| 2011 | -4.85 | -86.76% |
| 2010 | -36.63 | N/A |
Comparison Amarin (AMRN) P/E with competitors
Amarin (AMRN) P/E is -8.43.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -219.87% |
| PFE | Pfizer Inc | 11.65 | -238.18% |
| NVO | Novo Nordisk | 11.79 | -239.81% |
| GSK | GSK Plc | 12.10 | -243.51% |
| SNY | Sanofi | 12.12 | -243.76% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -263.86% |
| OGN | Organon & Company | 14.33 | -269.87% |
| BIIB | Biogen Inc | 17.41 | -306.38% |
| GILD | Gilead Sciences Inc | 17.75 | -310.40% |
| NVS | Novartis AG | 21.60 | -356.07% |
| JNJ | Johnson & Johnson | 22.09 | -361.89% |
| AMGN | AMGEN Inc | 24.75 | -393.47% |
| MRK | Merck & Co Inc | 26.93 | -419.27% |
| AZN | Astrazeneca plc | 28.44 | -437.24% |
| LLY | Lilly(Eli) & Company | 48.44 | -674.38% |
| ABBV | Abbvie Inc | 139.08 | -1749.07% |